Get ready to energize your life?
Top Offers Only Today
Support your health and step-up your mental focus
post in: News Date:22 Nov 2017, 11:26 views:2696
Heart Failure, coreg is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization see Drug Interactions (.4 Clinical Studies. Left Ventricular Dysfunction following Myocardial Infarction. Coreg is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40 (with or without symptomatic heart failure) see Clinical Studies (.
Hypertension, coreg is indicated for the management of essential hypertension see Clinical Studies (.3,.4 ).
It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics see Drug Interactions (.2 ). Coreg Dosage and Administration, coreg should treatment be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects. Heart Failure, dosage must BE individualized AND closely monitored bhysician during UP-titration.
Prior to initiation of Coreg, it is recommended that fluid retention be minimized. The recommended starting dose of Coreg.125 mg twice daily for 2 weeks.
If tolerated, patients may have their dose increased.25,.5, and 25 mg twice daily over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated. A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg (187 lbs).
Patients should be advised that initiation of treatment and (to a lesser extent) guidelines dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing.
During these periods, patients should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of Coreg from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of Coreg should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.
Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. The dose of Coreg should be reduced if patients experience bradycardia (heart rate less than 55 beats per minute). Episodes pediatric of dizziness or fluid retention during initiation of Coreg can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol.